Mesothelioma Immunotherapy

FDA-Approved Mesothelioma Immunotherapy (as of 2026)
Two first-line regimens, by trial and approval date
Drug Combination	Nivolumab + Ipilimumab
Pivotal Trial	CheckMate 743
FDA Approval	October 2, 2020
Indication	Unresectable malignant pleural mesothelioma (1L)
Median OS	18.1 vs. 14.1 mo (chemo); HR 0.74
Drug Combination	Pembrolizumab + Pemetrexed + Platinum
Pivotal Trial	IND227
FDA Approval	September 17, 2024
Indication	Unresectable advanced/metastatic MPM (1L)
Median OS	17.3 vs. 16.1 mo; HR 0.79; ORR 62%

Is Immunotherapy Effective for Mesothelioma, and Which Drugs Are FDA-Approved?

Executive Summary

Yes — immunotherapy is effective for mesothelioma, and as of 2026 there are two FDA-approved first-line immunotherapy regimens for unresectable malignant pleural mesothelioma (MPM):

1. Nivolumab + ipilimumab — approved by the FDA on October 2, 2020 based on the CheckMate 743 Phase III trial; the first FDA-approved frontline therapy for unresectable MPM in 16 years.
2. Pembrolizumab + pemetrexed + platinum chemotherapy — approved September 17, 2024 based on the Canadian Cancer Trials Group IND227 trial.

Both regimens deliver an overall-survival benefit over platinum-pemetrexed chemotherapy alone, and both are now codified in the 2025 ASCO mesothelioma guideline as standard first-line options. The choice between them is driven by histology, performance status, comorbidities, and patient preference.

The most striking long-term result comes from the 5-year update of CheckMate 743 (median follow-up 66.8 months — the longest ever reported for first-line immunotherapy in MPM), which demonstrated that 14 percent of nivolumab + ipilimumab patients were alive at 5 years versus 6 percent on chemotherapy — and that non-epithelioid MPM patients (sarcomatoid + biphasic) had a 5-year overall survival of 12 percent on immunotherapy versus 1 percent on chemotherapy (HR 0.48; 95% CI 0.33–0.68). The non-epithelioid effect is one of the largest subgroup benefits documented in mesothelioma oncology.

Immunotherapy is not a cure, and not every patient benefits. Response rates are modest in absolute terms (40 percent ORR for nivo+ipi; 62 percent for pembro+chemo), and immune-related adverse events ranging from mild rashes to potentially fatal pneumonitis or paraneoplastic encephalitis can occur with checkpoint inhibitors. But for a disease whose sole evidence-based first-line treatment for the prior 16 years was platinum + pemetrexed chemotherapy delivering median overall survival of approximately 12–13 months, the introduction of durable immunotherapy responses has been transformative.

This page is the procedural and clinical-context reference. Patient-eligibility detail, side-effect management, and active-trials information are summarized here; treatment-pathway comparison and stage-stratified survival data live at Mesothelioma_Prognosis, and active immunotherapy trials are documented at Clinical_Trials_Mesothelioma.

How Immunotherapy Works in Mesothelioma

The two FDA-approved mesothelioma immunotherapy regimens use immune checkpoint inhibitors (ICIs) that target two distinct pathways tumors use to evade the immune system.

• PD-1 / PD-L1 axis. Tumor cells often display the PD-L1 ligand on their surface, which binds the PD-1 receptor on T cells and effectively turns the T cell off. PD-1 inhibitors (nivolumab, pembrolizumab) and PD-L1 inhibitors (atezolizumab, durvalumab) block this binding so that activated T cells can recognize and attack tumor cells.
• CTLA-4 pathway. CTLA-4 is a checkpoint expressed on T cells that, when activated, dampens early T-cell activation. Anti-CTLA-4 antibodies (ipilimumab, tremelimumab) block this pathway and broaden the pool of T cells available to attack the tumor.

The dual-checkpoint regimen (nivolumab + ipilimumab) attacks both pathways simultaneously and produces durable responses in a meaningful minority of patients, especially in non-epithelioid histology where conventional chemotherapy is least effective. The chemoimmunotherapy regimen (pembrolizumab + pemetrexed + platinum) combines a single PD-1 blockade with the established platinum-pemetrexed backbone, producing higher response rates than chemotherapy alone with an additive overall-survival benefit.

FDA-Approved First-Line Regimens

Nivolumab + Ipilimumab (CheckMate 743) — FDA Approved October 2020

The FDA approved nivolumab + ipilimumab on October 2, 2020 for first-line treatment of adult patients with unresectable malignant pleural mesothelioma — the first new frontline approval for this disease since 2004.

The pivotal trial, CheckMate 743, was a multicentre, randomised, open-label Phase III study (NCT02899299) that randomised 605 patients 1:1 to either nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (for up to 2 years) versus cisplatin-or-carboplatin plus pemetrexed every 3 weeks (up to 6 cycles). The primary endpoint was overall survival.

Key efficacy data across follow-up timepoints:

Follow-up Timepoint	Median OS (Nivo+Ipi vs. Chemo)	Landmark OS Rate	Notes
Initial readout (Lancet 2021)	18.1 vs. 14.1 mo (HR 0.74; p=0.0020)	2-yr 41% vs. 27%	ORR 40% vs. 44%
5-year update (JCO 2026)	18.1 vs. 14.1 mo (HR 0.74)	5-yr 14% vs. 6%	5-yr PFS 8% vs. 0%

The 5-year update showed that 17 percent of immunotherapy responders maintained ongoing response at 5 years, versus 0 percent in the chemotherapy arm — a durability tail that defines the long-term value proposition of dual-checkpoint immunotherapy in MPM.

Histology-stratified outcomes (5-year update):

Histologic Subtype	ICI 5-yr OS	Chemo 5-yr OS	Hazard Ratio
Overall population	14%	6%	0.74 (95% CI 0.62–0.88)
Epithelioid	14%	8%	0.85 (95% CI 0.69–1.03)
Non-epithelioid	12%	1%	0.48 (95% CI 0.33–0.68)

The non-epithelioid subgroup result — near-elimination of the 5-year survival gap that previously defined this poor-prognosis histology — is the single strongest argument for dual-checkpoint immunotherapy in patients whose tumors are biphasic or sarcomatoid.

Pembrolizumab + Pemetrexed + Platinum (IND227) — FDA Approved September 2024

The FDA approved pembrolizumab + pemetrexed + cisplatin or carboplatin on September 17, 2024 for unresectable advanced or metastatic malignant pleural mesothelioma based on the Canadian Cancer Trials Group IND227 trial.

IND227 (NCT02784171) was a Phase II/III randomized trial of 440 patients comparing platinum-pemetrexed chemotherapy alone versus the same chemotherapy plus pembrolizumab.

• Median overall survival: 17.3 months (chemo + pembro) vs. 16.1 months (chemo alone); HR 0.79 (95% CI 0.64–0.98); p=0.0324
• Objective response rate: 62 percent (chemo + pembro) vs. ~38 percent (chemo alone) — near-doubling of response rate
• 3-year overall survival: 25% vs. 17%
• Grade 3–4 adverse events: 27% (chemo + pembro) vs. 15% (chemo alone)

The chemoimmunotherapy regimen produces materially higher response rates than chemotherapy alone — clinically important when rapid disease control is needed for symptomatic patients — with an additive overall-survival benefit. Updated WCLC 2025 analysis confirmed the OS benefit was maintained over extended follow-up.

Drug Comparison: Nivolumab + Ipilimumab vs. Pembrolizumab + Chemotherapy

Feature	Nivolumab + Ipilimumab	Pembrolizumab + Pemetrexed + Platinum
Pivotal trial	CheckMate 743 (n=605)	IND227 (n=440)
FDA approval	October 2, 2020	September 17, 2024
Indication	Unresectable MPM, first-line	Unresectable advanced/metastatic MPM, first-line
Median OS (vs. chemo)	18.1 vs. 14.1 mo; HR 0.74	17.3 vs. 16.1 mo; HR 0.79
ORR	40%	62%
5-year OS (overall)	14% vs. 6% chemo	25% at 3 years (longer follow-up pending)
Best-fit subgroup	Non-epithelioid (HR 0.48 at 5-yr)	Symptomatic patients needing rapid response
Grade 3–4 AE rate	30%	27%
Treatment duration	Up to 2 years	Pembrolizumab can continue beyond chemo cycles

Patient Eligibility

Eligibility for first-line immunotherapy under the FDA-approved indications is broadly:

• Diagnosis — Histologically confirmed unresectable malignant pleural mesothelioma (epithelioid, biphasic, or sarcomatoid).
• Treatment line — First-line; no prior systemic therapy for mesothelioma. Immunotherapy is also active in some second-line settings, but the FDA-approved indication is first-line.
• Performance status — Adequate performance status (ECOG 0–1 in trial populations; 2 may be considered case-by-case).
• Organ function — Adequate cardiac, renal, hepatic, and pulmonary reserve.
• Autoimmune disease history — Active autoimmune disease, prior solid-organ transplant, or chronic immunosuppressive therapy is generally an exclusion or relative contraindication.
• PD-L1 status — Not used to determine eligibility. PD-L1, tumor mutational burden, and microsatellite-instability testing are not predictive of immunotherapy benefit in MPM and the 2025 ASCO guideline explicitly recommends against using them to select therapy.

The choice between the two FDA-approved regimens is typically driven by:

• Histology. Non-epithelioid MPM derives the largest benefit from dual-checkpoint immunotherapy (nivo+ipi); epithelioid MPM has three reasonable first-line options (chemotherapy, nivo+ipi, or pembro+chemo).
• Symptom acuity. Symptomatic patients who need rapid disease control may benefit from the higher ORR of pembro+chemo.
• Comorbidity profile. Patients with renal impairment, peripheral neuropathy, or other limits on platinum exposure may favor dual immunotherapy.
• Patient preference. Both regimens have meaningful side-effect profiles; the choice is shared decision-making at a mesothelioma specialist center.

Side Effects and Their Management

Immune checkpoint inhibitors can cause immune-related adverse events (irAEs) arising from off-target activation of T cells against healthy tissues. The most common categories:

• Skin — rash, pruritus, vitiligo (usually grade 1–2; topical corticosteroids).
• Endocrine — thyroiditis, hypophysitis, adrenal insufficiency, type 1 diabetes (often requires lifelong hormone replacement).
• Gastrointestinal — colitis, hepatitis (range from mild diarrhea to severe immune-mediated colitis requiring high-dose systemic corticosteroids).
• Pulmonary — pneumonitis (potentially severe; requires prompt steroid therapy and discontinuation of ICI).
• Neurologic — rare but can be severe — encephalitis (including paraneoplastic anti-Ma2 encephalitis), Guillain-Barré syndrome, myasthenic syndromes.
• Cardiac — myocarditis (rare but high-mortality).
• Renal — interstitial nephritis.

Across the CheckMate 743 and IND227 trials, Grade 3–4 treatment-related adverse-event rates were approximately 30 percent for nivo+ipi and 27 percent for pembro+chemo — broadly comparable to chemotherapy alone in incidence but with a different toxicity profile.

Management principles:

• Multidisciplinary monitoring (oncology + endocrinology + dermatology + pulmonology + hepatology as needed).
• Early steroid therapy for grade 2+ irAEs; high-dose IV methylprednisolone for severe events.
• Permanent ICI discontinuation for grade 3–4 events in most cases.
• Patients who discontinue ICIs due to toxicity often retain durable benefit — in CheckMate 743 long-term follow-up, a meaningful share of patients who discontinued for treatment-related AEs maintained response years after discontinuation.

Comparison With Chemotherapy Alone

Before October 2020, platinum (cisplatin or carboplatin) plus pemetrexed was the sole evidence-based first-line treatment for unresectable MPM, delivering a median overall survival of approximately 12–13 months and an ORR of approximately 40 percent. The MAPS trial (2016) demonstrated that adding bevacizumab to platinum-pemetrexed improved median OS modestly (18.8 vs. 16.1 months); bevacizumab was never FDA-approved for MPM but is used off-label under a category-1 NCCN recommendation.

Immunotherapy's contribution over chemotherapy alone is most visible in three places:

1. Long-term durability. 5-year overall survival of 14 percent on nivo+ipi vs. 6 percent on chemo (CheckMate 743) means dual-checkpoint immunotherapy more than doubles long-term survival.
2. Non-epithelioid benefit. The largest single subgroup benefit in modern mesothelioma oncology — 12 percent vs. 1 percent 5-year OS in non-epithelioid disease (HR 0.48).
3. Response rates with chemoimmunotherapy. IND227's 62 percent ORR with pembro+chemo vs. ~38 percent with chemo alone is clinically meaningful for symptom-driven response demands.

For surgically operable epithelioid MPM with low PCI/limited disease, surgery (including HIPEC for peritoneal disease) remains a curative-intent pathway; immunotherapy plays an increasing perioperative role under investigation. See HIPEC for the surgical-pathway reference and Pleural_Mesothelioma for the pleural-disease context.

Future Directions

The mesothelioma immunotherapy pipeline has expanded substantially since 2020.

• Perioperative immunotherapy. Phase II/III trials are evaluating perioperative nivolumab ± ipilimumab in operable MPM, with promising preliminary results suggesting durable disease control beyond the standard surgery-plus-chemo paradigm.
• CAR-T cell therapy — Mesothelin-targeted chimeric antigen receptor T-cell therapies are in Phase I/II trials for advanced mesothelioma, with response signals in a minority of patients.
• Cancer vaccines. UV1 (telomerase peptide vaccine) received FDA Fast Track for mesothelioma; tumor-treating fields combinations and personalized neoantigen vaccines are active investigation areas.
• Novel checkpoint combinations. Trial activity targeting LAG-3, TIM-3, and TIGIT in combination with PD-1 / PD-L1 blockade is increasing; eVOLVE-Meso (volrustomig, anti-PD-1/CTLA-4 bispecific) is in Phase III.
• Biomarker-guided strategies. Although PD-L1 has proven inconsistent as a predictive biomarker, exploratory analyses identifying baseline myeloid-derived suppressor cells and BAP1 status as prognostic and potentially predictive markers are informing the next generation of trial designs.

For an active list of trials enrolling in the United States, see Clinical_Trials_Mesothelioma. For perioperative and surgical-pathway integration, see Pleural_Mesothelioma and HIPEC (peritoneal). For cost-of-care considerations, including the financial-toxicity profile of immunotherapy regimens, see Mesothelioma_Treatment_Costs.

See also

• Pleural_Mesothelioma — Disease overview, pathology, and natural history of pleural disease
• Mesothelioma_Prognosis — Stage-stratified survival, treatment-pathway comparisons
• Clinical_Trials_Mesothelioma — Active immunotherapy and combination trials
• Mesothelioma_Treatment_Costs — Direct-cost and financial-toxicity context for immunotherapy regimens
• Mesothelioma_Specialists — High-volume specialist centers offering immunotherapy and combination protocols
• Chemotherapy_for_Mesothelioma — Platinum-pemetrexed backbone and combination chemotherapy reference
• HIPEC — Surgical-pathway reference for peritoneal mesothelioma
• Mesothelioma_Diagnosis — Diagnostic workup and pathology subtype determination
• Mesothelioma — Top-level disease hub